Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTDSS1 | P48651 | 11/20 | 0.40 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31667707 | 0.93 | PTDSS1 (0.40) | PTDSS1IL4I1CYP11B1CYP11B2S1PR1 | |
| SCHEMBL31667211 | 0.88 | PTGDR (0.44) | IL4I1PTGDRMAPT | |
| SCHEMBL31666961 | 0.85 | IL4I1 (0.46) | IL4I1MEN1LMNAMAPTKMT2A | |
| SCHEMBL31667642 | 0.85 | IL4I1 (0.46) | IL4I1MEN1LMNAMAPTKMT2A | |
| SCHEMBL31667115 | 0.85 | IL4I1 (0.46) | IL4I1MEN1LMNAMAPTKMT2A | |
| SCHEMBL31666976 | 0.85 | IL4I1 (0.46) | IL4I1MEN1LMNAMAPTKMT2A | |
| SCHEMBL31667552 | 0.83 | NOS1 (0.51) | IL4I1MEN1KMT2AGRIN1 | |
| SCHEMBL31666978 | 0.82 | GRIN2D (0.41) | IL4I1PTGDRGRIN1 | |
| SCHEMBL31667589 | 0.82 | NOS1 (0.41) | IL4I1CYP11B1CYP11B2LMNAMAPT | |
| SCHEMBL31667564 | 0.82 | IL4I1 (0.39) | IL4I1PTGDRMEN1KMT2AGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | SIRONAX LTD (KY) | 2026-03-19 | — | — | US | disclosed |
| EP-4590674-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2025-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | NAMPT, NNMT, SARM1 | PTDSS1 2457/4885IL4I1 2872/4885CYP11B1 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.